Novavax, Inc. (NASDAQ:NVAX) – B. Riley issued their FY2019 EPS estimates for shares of Novavax in a note issued to investors on Wednesday, November 27th. B. Riley analyst M. Mamtani expects that the biopharmaceutical company will post earnings of ($5.17) per share for the year. B. Riley has a “Buy” rating and a $12.00 price target on the stock. B. Riley also issued estimates for Novavax’s Q4 2019 earnings at ($0.60) EPS, Q1 2020 earnings at ($0.56) EPS, Q2 2020 earnings at ($0.55) EPS, Q3 2020 earnings at ($0.67) EPS, Q4 2020 earnings at ($0.68) EPS and FY2020 earnings at ($2.42) EPS.
Novavax (NASDAQ:NVAX) last announced its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.98) by $0.24. The business had revenue of $2.51 million during the quarter, compared to analyst estimates of $4.40 million. During the same quarter last year, the company posted ($2.40) earnings per share.
Several other brokerages have also recently issued reports on NVAX. Oppenheimer decreased their price target on shares of Novavax from $25.00 to $13.00 and set an “outperform” rating for the company in a research report on Tuesday, September 10th. HC Wainwright upped their price target on shares of Novavax from $10.00 to $17.00 and gave the company a “buy” rating in a research report on Wednesday, August 14th. Citigroup decreased their price target on shares of Novavax from $19.00 to $15.00 and set a “buy” rating for the company in a research report on Tuesday, September 24th. Zacks Investment Research cut shares of Novavax from a “hold” rating to a “sell” rating in a research report on Friday, October 25th. Finally, LADENBURG THALM/SH SH restated a “buy” rating and issued a $27.50 price target on shares of Novavax in a research report on Friday, November 8th. Three investment analysts have rated the stock with a sell rating, four have issued a hold rating and six have given a buy rating to the stock. Novavax has a consensus rating of “Hold” and an average target price of $28.85.
Shares of NASDAQ NVAX opened at $4.85 on Monday. Novavax has a 52-week low of $3.54 and a 52-week high of $51.60. The firm has a 50 day moving average price of $4.32 and a two-hundred day moving average price of $5.24. The stock has a market cap of $104.71 million, a P/E ratio of -0.49 and a beta of 1.90.
In other news, SVP John A. Herrmann III sold 3,643 shares of the stock in a transaction on Tuesday, September 17th. The shares were sold at an average price of $7.07, for a total transaction of $25,756.01. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Gregory M. Glenn sold 9,620 shares of the stock in a transaction on Friday, September 13th. The stock was sold at an average price of $6.18, for a total transaction of $59,451.60. Following the sale, the insider now owns 123 shares of the company’s stock, valued at $760.14. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 22,770 shares of company stock valued at $132,123. 3.30% of the stock is currently owned by corporate insiders.
Several institutional investors and hedge funds have recently bought and sold shares of the company. State Street Corp increased its position in shares of Novavax by 3.4% during the third quarter. State Street Corp now owns 424,189 shares of the biopharmaceutical company’s stock worth $2,129,000 after buying an additional 14,066 shares during the period. Creative Planning increased its position in shares of Novavax by 16.5% during the third quarter. Creative Planning now owns 92,344 shares of the biopharmaceutical company’s stock worth $464,000 after buying an additional 13,101 shares during the period. Ontario Teachers Pension Plan Board acquired a new stake in shares of Novavax during the second quarter worth $510,000. A.R.T. Advisors LLC acquired a new stake in Novavax in the second quarter worth $435,000. Finally, GSA Capital Partners LLP acquired a new stake in Novavax in the second quarter worth $197,000. Institutional investors own 26.74% of the company’s stock.
About Novavax
Novavax, Inc, together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company’s lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein recombinant nanoparticle vaccine with aluminum phosphate as an adjuvant that is in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase II clinical trial for treating seasonal influenza in older adults.
